NSCLC I
NSCLC II
MCRC I
MCRC II
Other
100
Where is the median OS for study E1594?
Hist Persp & Key Trials
Chemo standard (E1594)
100
Where is the NCCN recommendation for continuation/maintenance?
Duration Call
NCCN Continuation Rec.
OR
Treatment Algorithm
NCCN Continuation Rec.
100
Where is the data that shows Avastin is the only biologic to achieve the primary efficacy endpoints across 3 distinct IV 5-FU-based chemotherapy backbones in MCRC?
Avastin Foundation
Primary EP across 3 backbones
OR
Subgroup Efficacy
Primary EP across 3 backbones
OR
Second-line Efficacy
Primary EP across 3 backbones
100
Where is the E3200 K-M curve showing the significant increase in median PFS with Avastin plus FOLFOX4 compared to FOLFOX4 alone in second-line MCRC?
Second-line Efficacy
2L PFS (K-M)
100
Where is the Access Solutions services information?
Access Solutions
Access Solutions service structure
200
Where is the statement "15 mg/kg Q3W is the only dose of Avastin demonstrated to significantly increase OS in first-line metastatic non-squamous NSCLC?"
Hist Persp & Key Trials
15 mg/kg q3w increase OS
OR
Study E4599
15 mg/kg q3w increase OS
OR
Duration
15 mg/kg q3w increase OS
OR
Treatment Algorithm
15 mg/kg q3w increase OS
OR
Dose
15 mg/kg q3w increase OS
200
Where is the meaningful 1-year and 2-year survival rates in first-line metastatic non-squamous NSCLC?
Study E4599
OS (K-M)
200
Where is the additional safety data on Avastin that was collected from >5,400 patients across 3 large observational studies?
Blended Foundation
Safety statement
OR
First-line Efficacy
Safety statement
OR
Subgroup Efficacy
Safety statement
OR
Second-line Efficacy
Safety statement
200
Where is the E3200 bar chart showing ORR more than doubled with Avastin plus FOLFOX compared to FOLFOX alone in second-line MCRC?
Second-line Efficacy
2L ORR
200
Where is MOA graphic showing the impact of Avastin on VEGF over time?
MOA Call
Proposed early and later effects
300
Where is Mark Kris’s quote on the trifecta of Avastin benefits?
Study E4599
Trifecta of benefits
300
Where is the safety results for study E4599?
Study E4599
Safety profile
300
Where is the graph showing the percentage of patients treated with Avastin to disease progression in studies 2107 and N016966?
First-line Efficacy
966 vs. 2107 Duration
300
Where is select patient eligibility criteria for study 2107?
First-line Efficacy
Pt. Eligibility
300
Where is the pan-tumor graphic demonstrating efficacy results for Avastin-based therapy in two distinct tumor types?
Pan Tumor
Efficacy/safety
Patient efficacy chevrons
400
Where is the histology pie chart for study E4599?
Study E4599
Histologies pie chart
400
Where is Avastin stated to be a standard of care?
Hist Persp & Key Trials
Avastin + PC a Standard of Care
400
Where is the retrospective KRAS analysis table for study 2107?
First-line Efficacy
KRAS Table
OR
Additional Materials
KRAS Reactive Quick Hit
400
Where is the timeline showing FDA approved PI timeline for withholding Avastin before and after surgery to address surgery and wound healing complications?
First-line Efficacy
Surgery timeline
OR
Subgroup Efficacy
Surgery timeline
400
Where is the pan-tumor graphic demonstrating that Avastin can be given at approved dose until disease progression or unacceptable toxicity in two distinct tumor types?
Pan Tumor
Dose/Duration
Pan tumor treat until disease progression
M
e
n
u